Immunocore Holdings plc - ADR
IMCR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.55B
Close$
$-21.06
170.3% downside
Current Fair Value
170.3% downsideOvervalued by 170.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.55 Billion |
|---|---|
| Enterprise Value | $1.08 Billion |
| Earnings per Share | $-0.71 |
| Beta | 0.82 |
| Outstanding Shares | 51,559,315 |
Return
| Return on Equity | -5.80% |
|---|---|
| Return on Assets | -2.16% |
| Return on Invested Capital | -1.49% |
Valuation & Multiples
| P/E Ratio | -47.31 |
|---|---|
| PEG | 2.47 |
| Price to Sales | 4.28 |
| Price to Book Ratio | 3.74 |
| Enterprise Value to Revenue | 2.67 |
| Enterprise Value to EBIT | -80.37 |
| Enterprise Value to Net Income | -45 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 6, 2026
EPS
-$0.28
Est. -$0.12Revenue
$102.22 M
Est. $152.09 MNext Earnings Call
Expected Date
February 24, 2027
EPS Estimate
-$0.23
Consensus analyst estimateRevenue Estimate
$149.27 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 1.00, calls and puts are about even.
| Put/Call Ratio | 1.0000▼ 203.87% |
|---|---|
| Total Calls | 30,000▼ 82.67% |
| Total Puts | 30,000▼ 94.30% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.31%▼ 99.92% |
|---|---|
| Total Invested | $35.71M▼ 97.84% |
| Investors Holding | 21▼ 124.00% |
About Immunocore Holdings plc
2,020 employees
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of disea...